Trials / Completed
CompletedNCT00238901
Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver Transplantation
Efficacy and Safety of Basiliximab in HCV+ Patients Undergoing Liver Transplantation, as Compared With Steroids, Both Given in Combination With Cyclosporine and Mycophenolate Mofetil (MMF)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 194 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
The natural history of HCV infection in liver transplant recipients may be accelerated when compared to that in patients with normal immune systems. The objective of this trial is to assess the efficacy and safety of basiliximab, in combination with cyclosporin and MMF on the success rate of liver transplants for HCV related cirrhosis, in comparison with standard steroid treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Basiliximab |
Timeline
- Start date
- 2002-12-01
- Primary completion
- 2005-07-01
- First posted
- 2005-10-14
- Last updated
- 2010-09-01
Source: ClinicalTrials.gov record NCT00238901. Inclusion in this directory is not an endorsement.